Douglas Lane & Associates, LLC Geron Corp Transaction History

Douglas Lane & Associates, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 16, 2023	SELL	$2.11 - $3.28 $10,550 - $16,400	-5,000 Reduced 6.59%	70,900 $150,000
Q2 2023 Jul 19, 2023	SELL	$1.97 - $3.69 $11,820 - $22,140	-6,000 Reduced 7.33%	75,900 $243,000
Q1 2023 Apr 17, 2023	SELL	$2.14 - $3.4 $4,280 - $6,800	-2,000 Reduced 2.38%	81,900 $177,000
Q4 2022 Jan 17, 2023	BUY	$2.03 - $2.42 $170,316 - $203,038	83,900 New	83,900 $203,000

281

492M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.11B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Douglas Lane & Associates, LLC, based on Form 13F filings with the SEC.

Stay updated on Douglas Lane & Associates, LLC with notifications on news.